Business
Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants with insufficient response to
About this update from Scilex Holding Company
[{"type":"text","content":"Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post-hoc analysis of two Phase 3 randomized clinical trials.In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB®-treated arm achieved 2-hour pain freedom (the gold standard for efficacy endpoint in migraine) than placebo (33.3% vs. 14.3%, p=0.0036). The likelihood of achieving pain freedom was 200% greater with ELYXYB® than with placebo (OR=3.0). PALO ALTO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced it will be presenting a poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be held in San Diego, CA on June 13-16, 2024. Presenting Author: Richard B. Lipton, M.D., Director of the Montefiore Headache Center and Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine. Poster Session 1 on June 13, 2024 at 6:00PM PT to 7:30PM PT. The poster presentation will describe the efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post hoc analysis of two Phase 3 randomized clinical trials. Key highlights of the ELYXYB® (celecoxib oral solution) presentation: Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post-hoc analysis of two Phase 3 randomized clinical trials.In a post-hoc analysis of two Phase 3 randomized clinical trials, the efficacy of ELYXYB® was compared with placebo in patients who were previously treated with triptans.In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB®-treated arm achieved 2-hour pain freedom (the gold standard for efficacy endpoint in migra...